Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Rocket Pharmaceuticals, Inc. RCKT ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:

• Citi's 15^th Annual BioPharma Virtual Conference
  • Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Thursday, September 10, 2020, at 1:30 p.m. Eastern Time.
  • Jonathan D. Schwartz, M.D., Chief Medical Officer and Senior Vice President, is scheduled to participate on a panel for Benign Hematology on Thursday, September 10, 2020, at 4:15 p.m. Eastern Time.

• Morgan Stanley's 18^th Annual Global Healthcare Virtual Conference
  • Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Thursday, September 17, 2020, at 2:00 p.m. Eastern Time.

A live audio webcast of the presentations will be available on the Investors section of the company's website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. RCKT ("Rocket") is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005151/en/